Silence Therapeutics said it has named Max Herrmann as its new CFO.
Herrmann was most recently CFO of Intercytex, a public company focused on regenerative medicine. Before that, he spent 10 years as a sell-side equity analyst, most recently at ING. He also previously served as financial controller for Onyx Pharmaceuticals.
He holds a degree in microbiology from the University of Kent.